Glecaprevir and pibrentasvir and Tybost

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Cobicistat may increase the blood levels of glecaprevir. This may increase the risk of liver problems that can occasionally occur during treatment with glecaprevir. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact. You should seek immediate medical attention if you have fever, chills, joint pain or swelling, unusual bleeding or bruising, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, abdominal pain, dark urine, pale stools, and/or yellowing of the skin or eyes, as these may be signs and symptoms of liver damage. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

MONITOR: Coadministration with cobicistat may significantly increase the plasma concentrations of glecaprevir. The proposed mechanism is inhibition of organic anion transporting polypeptide (OATP) 1B1-mediated hepatic uptake of glecaprevir by cobicistat. Inhibition of P-glycoprotein-mediated intestinal efflux and CYP450 3A4-mediated metabolism of glecaprevir may also contribute. When glecaprevir-pibrentasvir 300 mg-120 mg once daily was administered with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide 150 mg/150 mg/200 mg/10 mg once daily to 11 study subjects, glecaprevir peak plasma concentration (Cmax), systemic exposure (AUC) and trough plasma concentration (Cmin) increased by approximately 2.5-, 3.1- and 4.6-fold, respectively. Pibrentasvir Cmax was unaffected, but AUC and Cmin increased by nearly 1.6- and 1.9-fold, respectively. In addition, elvitegravir Cmax, AUC and Cmin were also increased by approximately 1.4-, 1.5- and 1.7-fold, respectively, while tenofovir AUC and Cmin were increased by nearly 1.3- and 1.4-fold, respectively. High plasma levels of glecaprevir may increase the risk of adverse effects such as alanine aminotransferase (ALT) and bilirubin elevations.

MANAGEMENT: According to the manufacturer, no dosage adjustment is necessary for glecaprevir-pibrentasvir during coadministration with cobicistat. However, the potential for increased adverse effects of glecaprevir-pibrentasvir should be considered.

Glecaprevir and pibrentasvir

Generic Name: glecaprevir / pibrentasvir

Brand name: Mavyret

Synonyms: Glecaprevir and Pibrentasvir

What is Glecaprevir and pibrentasvir?

Tybost

Generic Name: cobicistat

Brand name: Tybost

Synonyms: n.a.

What is Tybost?